CYTK Q4 2021 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$56M+727.1% YoY

Gross Profit

$12M21.8% margin

Operating Income

-$22M-39.0% margin

Net Income

-$31M-55.0% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+922.6%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$62M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$841M

Total Liabilities

$597M

Stockholders' Equity

$244M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$56M	$7M	+727.1%
Gross Profit	$12M	-$22M	+153.8%
Operating Income	-$22M	-$36M	+40.4%
Net Income	-$31M	-$44M	+30.4%

Revenue Segments

License

$55M99%

Research And Development

$744,0001%